(Q36438779)

14 August 2017

1 reference

title

Drug insight: antagonists of tumor-necrosis factor-alpha in the treatment of inflammatory bowel disease (English)

1 reference

inflammatory bowel diseases

14 August 2017

main subject

0 references

author name string

John T Chang

series ordinal

1

1 reference

14 August 2017

Gary R Lichtenstein

series ordinal

2

1 reference

14 August 2017

language of work or name

English

0 references

publication date

1 April 2006

1 reference

Nature Reviews Gastroenterology & Hepatology

14 August 2017

published in

1 reference

14 August 2017

volume

3

1 reference

14 August 2017

issue

4

1 reference

14 August 2017

page(s)

220-228

1 reference

New concepts in the pathophysiology of inflammatory bowel disease

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0447

Cutaneous nocardiosis complicating management of Crohn's disease with infliximab and prednisone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0447

Case reports of heart failure after therapy with a tumor necrosis factor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0447

The immunological and genetic basis of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0447

7 January 2021

NOD2 and Crohn's disease: loss or gain of function?

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0447

7 January 2021

Tumor necrosis factor: biology and therapeutic inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0447

7 January 2021

Role of cytokines in the pathogenesis of inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0447

7 January 2021

Tumour necrosis factor alpha in stool as a marker of intestinal inflammation

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0447

7 January 2021

Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0447

7 January 2021

Oxazolone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated by IL-13-producing NK-T cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0447

7 January 2021

Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0447

7 January 2021

Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0447

7 January 2021

Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0447

7 January 2021

Soluble tumor necrosis factor (TNF) receptor-1 induces apoptosis via reverse TNF signaling and autocrine transforming growth factor-beta1.

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0447

7 January 2021

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0447

7 January 2021

Infliximab for the treatment of fistulas in patients with Crohn's disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0447

7 January 2021

Infliximab maintenance therapy for fistulizing Crohn's disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0447

7 January 2021

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0447

7 January 2021

Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0447

7 January 2021

CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0447

7 January 2021

Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0447

7 January 2021

Infliximab for induction and maintenance therapy for ulcerative colitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0447

7 January 2021

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0447

7 January 2021

Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0447

7 January 2021

The incidence and management of infusion reactions to infliximab: a large center experience

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0447

7 January 2021

The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0447

7 January 2021

Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0447

7 January 2021

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0447

7 January 2021

Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0447

7 January 2021

Pneumocystis carinii pneumonia during maintenance anti-tumor necrosis factor-alpha therapy with infliximab for Crohn's disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0447

7 January 2021

Invasive Pulmonary Aspergillosis Associated with Infliximab Therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0447

7 January 2021

Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0447

7 January 2021

Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failu

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0447

7 January 2021

Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0447

7 January 2021

Autoimmune hepatitis associated with infliximab in a patient with psoriatic arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0447

7 January 2021

Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0447

7 January 2021

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0447

7 January 2021

Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0447

7 January 2021

Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-cont

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0447

7 January 2021

A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0447

7 January 2021

An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0447

7 January 2021

A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0447

7 January 2021

Treatment of active Crohn's disease with onercept (recombinant human soluble p55 tumour necrosis factor receptor): results of a randomized, open-label, pilot study

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0447

7 January 2021

Treatment of ulcerative colitis with an engineered human anti-TNFalpha antibody CDP571.

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0447

7 January 2021

Identifiers

DOI

10.1038/NCPGASTHEP0447

1 reference

Dimensions Publication ID

14 August 2017

1026307002

0 references

1 reference